Brokerages Set Scholar Rock Holding Corporation (NASDAQ:SRRK) PT at $56.00

Scholar Rock Holding Corporation (NASDAQ:SRRK) has been assigned a consensus recommendation of “Buy” from the eighteen brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have issued a buy rating and five have issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $56.00.

Several equities analysts have recently weighed in on SRRK shares. HC Wainwright raised their target price on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a report on Tuesday, April 21st. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday, March 3rd. BMO Capital Markets increased their price target on Scholar Rock from $50.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, March 4th. Finally, Citigroup increased their price target on Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $47.38 on Tuesday. The company has a market capitalization of $5.68 billion, a P/E ratio of -13.20 and a beta of 0.70. The business’s 50 day moving average is $46.68 and its two-hundred day moving average is $43.99. Scholar Rock has a 12-month low of $27.07 and a 12-month high of $51.63. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter last year, the firm posted ($0.67) earnings per share. Analysts expect that Scholar Rock will post -3.18 EPS for the current fiscal year.

Insider Transactions at Scholar Rock

In related news, COO Keith Woods sold 10,220 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $506,605.40. Following the completion of the sale, the chief operating officer owned 620,055 shares of the company’s stock, valued at approximately $30,736,126.35. This trade represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David Hallal sold 30,615 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $1,517,585.55. Following the completion of the sale, the chief executive officer directly owned 1,639,034 shares of the company’s stock, valued at approximately $81,246,915.38. This represents a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 71,975 shares of company stock valued at $3,546,591. 13.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. IFP Advisors Inc increased its stake in Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after acquiring an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Scholar Rock during the fourth quarter worth $30,000. Summit Securities Group LLC acquired a new stake in Scholar Rock during the fourth quarter worth $31,000. EverSource Wealth Advisors LLC increased its stake in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after acquiring an additional 525 shares during the last quarter. Finally, Hilton Head Capital Partners LLC acquired a new stake in Scholar Rock during the fourth quarter worth $44,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).